Kammer R B, Short L J
Infection. 1979;7 Suppl 6:631-5. doi: 10.1007/BF01659754.
Cefaclor, a new semisynthetic cephalosporin antibiotic for oral use, was studied by 62 clinical investigators in six countries in 1493 adult and paediatric patients. The pooled data reveal that satisfactory clinical responses were obtained in 80% of urinary tract infections, 87% of upper respiratory tract infections, 90% of cases of otitis media, 99% of lower respiratory tract infections, and 96% of skin and skin structure infections. Administration of this antibiotic was associated with a low incidence of adverse reactions including gastrointestinal (2.6%) and hypersensitivity (1.5%). Of particular clinical interest were the outstanding results obtained in the treatment of otitis media and lower respiratory tract infections.
头孢克洛是一种新型口服半合成头孢菌素抗生素，六个国家的62名临床研究人员对1493例成人和儿童患者进行了研究。汇总数据显示，尿路感染的临床有效率为80%，上呼吸道感染为87%，中耳炎为90%，下呼吸道感染为99%，皮肤及皮肤结构感染为96%。使用这种抗生素时不良反应发生率较低，包括胃肠道反应（2.6%）和过敏反应（1.5%）。特别值得临床关注的是在中耳炎和下呼吸道感染治疗中取得的出色疗效。
